Archives
- 2018-07
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
How does APC C recognize its substrates and catalyze
2019-07-18
How does APC/C recognize its substrates and catalyze their ubiquitylation? How are the outcomes and timing of these activities regulated? These questions have driven a decade of structural studies that begin to explain how APC/C interacts with coactivators, substrates, and E2s, and how these interactions are tightly controlled by phosphorylation and inhibitory proteins to prevent premature cell division and collateral catastrophic consequences like Alizarin (reviewed in 13, 14).
-
br Advent of SMEPT br SMEPT for localized synthesis
2019-07-17
Critical evaluation and outlook Examples discussed in this review present SMEPT as a methodology for localized drug synthesis – a unique opportunity for site specific therapeutic interventions using implantable biomaterials.
-
Patients with a tumor of
2019-07-16
Patients with a tumor of 4 cm or greater were more likely to have lymph node or tumor metastasis (Fisher’s test p = 0.0001 and 0.0003, respectively).
-
Previously we had proposed three possible models
2019-07-15
Previously we had proposed three possible models, with one being that hCrm1 fundamentally interacted more favorably or strongly with Rev-RRE complex, compared to mCrm1.
-
br Conclusion and future perspectives LDL cholesterol loweri
2019-07-13
Conclusion and future perspectives LDL cholesterol-lowering therapy is essential for cardiovascular risk reduction. On the background of a high inter-personal variation of cholesterol synthesis and cholesterol AZ 10417808 the efficacy of cholesterol lowering, both, with statins and with ezetimibe exhibits a wide variation.
-
Hello world!
2018-07-29
14781 records 986/986 page Previous First page 上5页 986